Non alcoholic fatty liver disease assessment;Mise au point d'une stéatopathie non alcoolique

Revue Medicale de Bruxelles

Volumn 33, Issue 4, 2012, Pages 205-211

  Juriens, I ^a   Rigaux, J ^a   Blero, D ^a  

^a Centre Hospitalier Universitaire de Charleroi   (Belgium)

Author keywords

Liver disease; Metabolic syndrome; NAFLD; NASH

Indexed keywords

ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC HEPATITIS; COLON CANCER; COMORBIDITY; DISEASE SEVERITY; ELASTOGRAPHY; END STAGE LIVER DISEASE; FIBROSIS; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER DISEASE; METABOLIC DISORDER; MORTALITY; NONALCOHOLIC FATTY LIVER; PORTAL HYPERTENSION; STEATOSIS;

ALGORITHMS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; MODELS, BIOLOGICAL;

EID: 84867508379     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Szczepaniak LS, Nurenberg P, Leonard D et al. : Magnetic resonance spectroscopy to measure hepatic triglyceride content : prevalence of hepatic steatosis in the general population. Am J Physiology 2005; 288 : E462-8 (Pubitemid 40110657)
2. Bellentani S, Saccoccio G, Masutti F et al. : Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132 : 112-7 (Pubitemid 30044177)
3. Gupte P, Amarapurkar D, Agal S et al. : Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004; 19 : 854-8 (Pubitemid 39093200)
4. Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D : Liver damage in obese patients. Obes Surg 2002; 12 : 802-4 (Pubitemid 36135524)
5. Clark JM : The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (3 Suppl 1) : S5-10
6. Fan JG, Zhu J, Li XJ et al. : Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatology 2005; 43 : 508-14 (Pubitemid 41111434)
7. Browning JD, Szczepaniak LS, Dobbins R et al. : Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity. Hepatology 2004; 40 : 1387-95 (Pubitemid 39657013)
8. Angulo P : Medical progress : nonalcoholic fatty liver disease. N Engl J Med 2002; 346 : 1221-31
9. Torres DM, Harrison SA : Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134 : 1682-98 (Pubitemid 351615413)
10. Mofrad P, Contos MJ, Haque M et al. : Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37 : 1286-92 (Pubitemid 36667307)
11. Fracanzani AL, Valenti L, Bugianesi E et al. : Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels : a role for insulin resistance and diabetes. Hepatology 2008; 48 : 792-8
12. Angulo P, Keach JC, Batts KP, Lindor KD : Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30 : 1356-62
13. Tahan V, Canbakan B, Balci H et al. : Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepato-Gastroenterology 2008; 55 : 1433-8
14. Ratziu V, Massard J, Charlotte F et al. : Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2006; 6 : 6
15. Poynard T, Lassailly G, Diaz E et al.; FLIP consortium : Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity : meta analysis of individual patient data. PloS One 2012; 7 : e30325. Epub 2012 Mar 14
16. Cales P, Laine F, Boursier J et al. : Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50 : 165-73
17. Osawa H, Mori Y : Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes. J Clin Ultrasound 1996; 24 : 25-9 (Pubitemid 26005173)
18. Sanyal AJ : AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123 : 1705-25
19. Ryan CK, Johnson LA, Germin BI, Marcos A : One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transplantation 2002; 8 : 1114-22 (Pubitemid 35469871)
20. Mottin CC, Moretto M, Padoin AV et al. : The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obesity Surgery 2004; 14 : 635-7 (Pubitemid 38716583)
21. Jacobs JE, Birnbaum BA, Shapiro MA et al. : Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenology 1998; 171 : 659-64 (Pubitemid 28406126)
22. Mazhar SM, Shiehmorteza M, Sirlin CB : Non invasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009; 7 : 135-40
23. Fishbein M, Castro F, Cheruku S et al. : Hepatic MRI for fat quantitation : its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39 : 619-25 (Pubitemid 41061269)
24. Saadeh S, Younossi ZM, Remer EM et al. : The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterol 2002; 123 : 745-50 (Pubitemid 34977081)
25. Yoneda M, Fujita K, Inamori M et al. : Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56 : 1330-1 (Pubitemid 47300449)
26. Wong VWS, Vergniol J, Wong GLH et al. : Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51 454-62
27. Ong JP, Younossi ZM : Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liver Dis 2005; 9 : 617-34 (Pubitemid 41406391)
28. Adams LA, Angulo P : Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007; 11 : 25-35 (Pubitemid 46829969)
29. Kleiner DE, Brunt EM, Van Natta M et al. : Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 : 1313-21 (Pubitemid 40770284)
30. Ratziu V, Charlotte F, Heurtier A et al. : Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128 : 1898-1906 (Pubitemid 40824701)
31. Younossi ZM, Gramlich T, Yao CL et al. : Nonalcoholic fatty liver disease : assessment of variability in pathologic interpretations. Modern Pathology 1998; 11 : 560-5 (Pubitemid 28280720)
32. Sanyal AJ : AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123 : 1705-25
33. Angulo P : Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 : 1221-31
34. Charlton M : Nonalcoholic fatty liver disease : a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2 : 1048-58
35. Bugianesi E, Leone N, Vanni E et al. : Expanding the natural history of nonalcoholic steatohepatitis : From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123 : 134-40 (Pubitemid 34747534)
36. Adams LA, Lymp JF, St Sauver J et al. : The natural history of nonalcoholic fatty liver disease : a population-based cohort study. Gastroenterology 2005; 129 : 113-21 (Pubitemid 41002048)
37. Sanyal AJ, Yoon SK, Lencioni R : The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15 (Suppl 4) : 14-22
38. Promrat K, Kleiner DE, Niemeier HM et al. : Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 : 121-9
39. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA : Orlistat for overweight subjects with nonalcoholic steato-hepatitis : A randomized, prospective trial. Hepatology 2009; 49 : 80-6
40. Suzuki A, Lindor K, St Saver J et al. : Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43 : 1060-6 (Pubitemid 41627993)
41. Abdelmalek MF, Suzuki A, Guy C et al. : Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis seventy in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51 : 1961-71
42. Bassuk SS, Manson JE : Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005; 99 : 1193-204 (Pubitemid 41214540)
43. LaMonte MJ, Blair SN, Church TS : Physical activity and diabetes prevention. J Appl Physiol 2005; 99 : 1205-13 (Pubitemid 41214541)
44. Bauman AE : Updating the evidence that physical activity is good for health : an epidemiological review 2000-2003. J Sci Med Sport 2004; 7 : 6-19
45. Pan XR, Li GW, Hu YH et al. : Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20 : 537-44
46. Capanni M, Calella F, Biagini MR et al. : Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease : a pilot study. Aliment Pharmacol Ther 2006; 23 : 1143-51 (Pubitemid 43779354)
47. Targher G, Bertolini L, Scala L et al. : Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17 : 517-24 (Pubitemid 47176859)
48. Nseir W MA, Abu Mouch S, Grosovski M, Assy N : Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in patients with Non Alcoholic Fatty Liver Disease. Hepatology 2010 (Suppl); 52 : S1
49. Marchesini G, Pagotto U, Bugianesi E et al. : Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab 2003; 88 : 5674-9 (Pubitemid 38033034)
50. Bugianesi E, Marchesini G, Gentilcore E et al. : Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease : Role of insulin resistance and hepatic steatosis. Hepatology 2006; 44 : 1648-55 (Pubitemid 44953669)
51. Promrat K, Lutchman G, Uwaifo GI et al. : A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39 : 188-96 (Pubitemid 38461481)
52. Sanyal AJ, Mofrad PS, Contos MJ et al. : A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2 : 1107-15 (Pubitemid 40037642)
53. Ratzius V, Charlotte F, Bernhardt C et al.; LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis : results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51 : 445-53
54. Stein JL, Dong MH, Loomba R : Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis : Current status. Adv Ther 2009; 26 : 893-907. Epub 2009 Nov 16
55. Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA : Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis : a case series. Am J Gastroenterol 2010; 105 : 2707-9